Open AccessPhosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
Author(s) -
Anna Lidia Wojdaƚa,
Davide Chiasserini,
G. Bellomo,
Silvia Paciotti,
Lorenzo Gaetani,
Federico Paolini Paoletti,
Lucilla Parnetti
Publication year - 2022
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-220323
Subject(s) - biomarker , biology , cohort , immunoassay , microbiology and biotechnology , medicine , immunology , biochemistry , antibody
Phosphatidylethanolamine binding protein 1 (PEBP1) is a multifunctional protein, mainly known for its specific binding of phosphatidylethanolamine and the ability to suppress the Raf1-MAPK pathway. Its potential role as an Alzheimer's disease (AD) biomarker has been proposed in several studies. However, evaluation of its discriminative value in clinical cohorts is missing.